Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term “parasite protein synthesis” refers to the complex multi-component machinery by which parasitic protozoa (notably *Plasmodium falciparum*) translate genetic information into functional proteins. This machinery includes ribosomal subunits (e.g., 30S, 50S, 40S, 60S), essential translation factors, and diverse aminoacyl-tRNA synthetases (aaRSs), which catalyze the charging of tRNAs with their respective amino acids—a crucial step for protein elongation[1][5][9]. The protein synthesis pathway in *Plasmodium falciparum* is substantially divergent from those in humans, with unique components such as tRip for tRNA import and unusual multi-synthetase complexes[9]. Multiple enzymes within this system—including lysyl-, phenylalanyl-, threonyl-, and prolyl-tRNA synthetases—are now recognized as validated antimalarial drug targets, with several specific inhibitors showing efficacy in both laboratory and animal models[1][5]. Translation inhibitors kill the parasite by disrupting its ability to generate proteins required for growth, replication, and survival. Notes on correctness and specificity: - “Parasite protein synthesis” is **not** a single specific molecule, enzyme, or receptor, but encompasses the entire translation machinery of the parasite, incorporating many druggable proteins[1][5][9]. - For structured data, targets should ideally use the precise protein name (e.g., "Plasmodium falciparum lysyl-tRNA synthetase") rather than the whole synthesis process, since “Parasite protein synthesis” is too broad for canonical standardization. Therefore, **is_incorrect: true** (refers to a pathway/process, not a specific drug target entity). If a canonical target is required, specific translation factors or individual enzymes should be named instead (e.g., “Plasmodium falciparum lysyl-tRNA synthetase”).
Inhibition of protein synthesis via binding to the ribosomal subunit (e.g., doxycycline on 30S subunit)[1] - Inhibition of specific aminoacyl-tRNA synthetases, blocking aminoacylation and thus translation[1][5][9] - Inhibition of elongation factors or ribosomal assembly, suppressing parasite protein production
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Parasite protein synthesis machinery.